Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Summary

The main purpose of this trial is to determine whether Xingnaojing, intravenously administered within 24 hours of symptom onset, improves the daily living ability of acute ischemic stroke at 90 days.

Conditions

• Acute Ischemic Stroke
• Stroke, Acute
• Stroke, Ischemic

Interventions

DRUG

Xingnaojing injection

Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.

DRUG

Xingnaojing placebo injection

Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.

OTHER

Standard care

Guidelines-based standard care for acute ischemic stroke.

Sponsors & Collaborators

• Peking University Third Hospital

  collaborator OTHER

• Beijing Shuyi Hospital

  collaborator OTHER

• The Airport Hospital of Shunyi District Beijing

  collaborator UNKNOWN

• Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine

  collaborator OTHER

• The NO.4 People's Hospital of Hengshui

  collaborator UNKNOWN

• The Second Hospital of Hebei Medical University

  collaborator OTHER

• The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

  collaborator OTHER

• The Affiliated Hospital of Shaanxi University of Chinese Medicine

  collaborator UNKNOWN

• Tianshui Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• The Affiliated Hospital of Changzhi Academy of TCM

  collaborator UNKNOWN

• Zibo Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Shandong University of Traditional Chinese Medicine

  collaborator OTHER

• Zhejiang Provincial Hospital of TCM

  collaborator OTHER

• Zhejiang Provincial Tongde Hospital

  collaborator OTHER

• Second Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• People's Hospital of Quzhou

  collaborator OTHER

• Longhua Hospital

  collaborator OTHER

• The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine

  collaborator OTHER

• Taizhou Hospital of Traditional Chinese Medicine

  collaborator OTHER_GOV

• The First Affiliated Hospital of Guizhou University of TCM

  collaborator UNKNOWN

• Guangzhou Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• The First Affiliated Hospital of Guangxi University of Chinese Medicine

  collaborator UNKNOWN

• Liling Hospital of Traditional Chinese Medicine

  collaborator UNKNOWN

• Hunan Academy of Traditional Chinese Medicine Affiliated Hospital

  collaborator UNKNOWN

• Hubei Hospital of Traditional Chinese Medicine

  collaborator OTHER

• The First Hospital of Jilin University

  collaborator OTHER

• Anshan Central Hospital

  collaborator OTHER

• Affiliated Hospital of Liaoning University of Traditional Chinese Medicine

  collaborator OTHER

• The First Hospital of Qiqihar City

  collaborator UNKNOWN

• Haikou People's Hospital

  collaborator OTHER

• The Second People's Hospital of Anhui Province

  collaborator OTHER

• The Third Affiliated Hospital of Shenzhen University

  collaborator UNKNOWN

• The Third People's Hospital of Hubei Province

  collaborator OTHER

• The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

  collaborator OTHER

• The Third Hospital of Xi'an City

  collaborator UNKNOWN

• Dongzhimen Hospital, Beijing

  lead OTHER

Principal Investigators

• Ying Gao, MD · Dongzhimen Hospital

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-03-19

Primary Completion

2021-12-31

Completion

2021-12-31

Countries

• China

Study Locations